Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 3 Interventional

Trial of Myocet in Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT00294996

Public ClinicalTrials.gov record NCT00294996. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer

Study identification

NCT ID
NCT00294996
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sopherion Therapeutics
Industry
Enrollment
363 participants

Conditions and interventions

Conditions

Interventions

  • Myocet Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2005
Primary completion
Not listed
Completion
Not listed
Last update posted
Mar 30, 2009

Started 2006

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Scripps Cancer Center Clinical Research San Diego California 92121
University of Colorado Aurora Colorado 80045
Northwest Hematology/Oncology Associates Coral Springs Florida 33065
Osceola Cancer Center Kissimmee Florida 34741
UM/Sylvester Cancer Center Plantation Florida 33324
John B. Amos Cancer Center Columbus Georgia 31904
Clintell, Inc Skokie Illinois 60076
Hutchinson Clinic P.A. Hutchinson Kansas 67502
Western Maryland Health System Cumberland Maryland 21502
Brody School of Medicine @ ECU Greenville North Carolina 27834
Aultman Hospital Cancer Center Canton Ohio 44710
Hematology Oncology Consultants, Inc. Columbus Ohio 43235
Vita Hematology Oncology Bethlehem Pennsylvania 18015
Hematology & Oncology Associates of NEPA Dunmore Pennsylvania 18512
PA Oncology Hematology Asso Philadelphia Pennsylvania 19106
M. Francisco Gonzalez Columbia South Carolina 29203
Sioux Valley Clinic Sioux Falls South Dakota 57104
Tennessee Cancer Specialists Knoxville Tennessee 37920

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00294996, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 30, 2009 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00294996 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →